Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global acute respiratory syndrome treatment market size attained a value of USD 947.08 million in 2023, driven by the mutating variants of COVID-19 and other emerging respiratory syndromes. The market is estimated to grow at a CAGR of 10.1% during the forecast period of 2024-2032. With this growth rate, the market value is estimated to reach a value of USD 2251.50 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The small, elastic air sacs (alveoli) in the lungs experience fluid buildup, which results in acute respiratory distress syndrome (ARDS). Less oxygen enters circulation because of the fluid's ability to prevent the lungs from filling with enough air. The organs are deprived of the oxygen they require to function as a result.
People who are already critically ill or have severe injuries are more likely to develop ARDS. The primary symptom of ARDS, severe shortness of breath, typically appear a few hours to a few days after the injury or illness that caused it. Age and sickness severity both raise the probability of death. Among those who survive ARDS, some make a full recovery while others have lung damage that lasts for a lifetime.
The severity of ARDS's signs and symptoms might vary depending on the condition's origin, its severity, and whether the underlying heart or lung illness is present or not. They consist of severe breathlessness, breathing that is laboured and unusually quick, reduced blood pressure, dizziness, and excessive fatigue
The smallest blood arteries in the lungs leak fluid into the tiniest air sacs where the blood is oxygenated, which is the mechanical cause of ARDS. This fluid is typically kept in the vessels by a protective barrier. However, severe disease or injury can harm the membrane, resulting in fluid leakage and ARDS.
Sepsis: It is a dangerous and widespread bloodstream infection and is the most typical cause of ARDS.
Inhalation: Breathing in dangerous toxins. ARDS may develop as a result of breathing toxic gases, excessive smoke concentrationkis, aspirating vomit, or near-drowning incidents.
Pneumonia: All five lobes of the lungs are typically affected by severe pneumonia.
Injury: Chest, head, or any serious damage. Accidents that cause direct damage to the lungs or the area of the brain that regulates respiration include slips, trips, and falls.
Others like burns, major blood transfusions, and pancreatitis (pancreatic inflammation).
Majority of people who develop ARDS are already ill or injured. While it is unclear who will develop ARDS, several factors, like advanced age, history of tobacco and alcohol consumption, presence of chronic lung disease, or high-risk surgery could lead to higher vulnerability.
To assist in the diagnosis of ARDS, several diagnostic tests are employed. These tests identify the infection's source, evaluate the state of the lungs, and rule out other illnesses that present with comparable symptoms. Imaging, blood testing, and analysis of sputum (the mixture of saliva and mucus that is coughed up) are procedures that can be used to diagnose acute respiratory distress syndrome.
The percentage of patients with ARDS who are admitted to intensive care units is between 10 and 15 percent . Geographically, ARDS incidence varies and may be greater in the United States and Europe than in other regions. According to the acute respiratory syndrome market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Breakup by Drug Class:
Breakup by Route of Administration:
Based on the Treatment Channel:
Market Breakup by Region:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
No medication has been proven to be successful in preventing or treating ARDS. The goal of treatment is to keep the patient comfortable as the lungs heal. The objective of supportive care is to treat the injury that led to the development of ARDS and get enough oxygen into the blood and distributed to your body to stop damage.
Ventilator Support: Extra oxygen is required for all ARDS patients. Typically, oxygen alone is insufficient and excessive oxygen can harm the lungs. A ventilator is a device that facilitates breathing by helping to reopen closed airways. Through a face mask or a tube put into the windpipe, the patient is connected to the ventilator.
Prone Positioning: Patients with ARDS usually lie on their backs in bed. ARDS patients may occasionally be flipped over onto their stomachs to increase blood oxygen levels when oxygen and ventilator therapies are being used at high levels, but blood oxygen levels are still low. Proning is a technique that can temporarily raise blood oxygen levels. It is a challenging task, and some patients are too ill to benefit from this therapy.
Fluid Management: Patients with ARDS are given diuretics to make the patients urinate more frequently in an effort to flush the body of extra fluid and prevent it from accumulating in the lungs. Care must be taken since excessive fluid loss might reduce blood pressure and cause renal issues.
Extracorporeal Membrane Oxygenation (ECMO): In ECMO, blood is removed from the body and pumped across a membrane that adds oxygen and removes carbon dioxide before returning the blood to the body. This therapy carries a high risk and several potential drawbacks. It is not appropriate for all ARDS patients.
Due to the diverse aetiology and pathophysiology of ARDS, personalised therapy is intrinsically difficult. But repurposing medications that have been investigated in untargeted/unenriched populations could be just as inventive and promising for ARDS research as novel experimental therapeutics, including for COVID-19 ARDS. Timing, clinical phenotypes, and biologic phenotypes are some potential therapeutic targets.
Multiple medicines can also be promptly and flexibly investigated with adaptive clinical trial design. It is also possible to individually tailor supportive measures, such as ventilator management and hydration strategy. Novel therapeutics are also in the works, in addition to possible repurposing/targeting of current medications and supportive care techniques.
The report gives an in-depth analysis of the key players involved in the acute respiratory syndrome treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Route of Administration |
|
Breakup by Treatment Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The acute respiratory syndrome treatment market is driven by the rising respiratory issues, especially with the mutating variants of COVID-19 over the historical period.
Based on the drug classification, the market is categorised into vasoconstrictors, bronchodilators, steroids, antibiotics, nitric oxide, surfactants, sedatives and paralytics, among others.
Based on the class, the market is segmented into oral, parenteral, and inhalation, among others.
The treatment channels in this market are public and private.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
As fluid accumulates in your lungs' little, elastic air sacs (alveoli), acute respiratory distress syndrome (ARDS) develops. Less oxygen enters your circulation because of the fluid's ability to prevent your lungs from filling with enough air. This deprives your organs of the oxygen they require to function.
The key companies involved in this market are AIkido Pharma Inc., Aceto Corporation, Global, BioLife Inc Ltd, Faron Pharmaceuticals, PhaseBio Pharmaceuticals, Sage Therapeutics, Emergent BioSolutions, Direct Biologics, Kiniksa Pharmaceuticals, Ltd, Biomarck Pharmaceuticals, Ltd., Athersys, Inc. among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share